Emergent BioSolutions Inc.
EBS
$5.71
$0.203.63%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -33.73% | 15.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -33.73% | 15.35% | |||
| Cost of Revenue | -55.09% | -59.53% | |||
| Gross Profit | -16.87% | 350.69% | |||
| SG&A Expenses | -20.03% | -1.81% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.28% | -46.40% | |||
| Operating Income | -105.97% | 145.25% | |||
| Income Before Tax | -119.38% | 152.78% | |||
| Income Tax Expenses | -86.59% | 107.52% | |||
| Earnings from Continuing Operations | -127.26% | 140.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -127.26% | 140.55% | |||
| EBIT | -105.97% | 145.25% | |||
| EBITDA | -78.51% | 174.30% | |||
| EPS Basic | -126.71% | 140.17% | |||
| Normalized Basic EPS | -124.95% | 145.74% | |||
| EPS Diluted | -128.14% | 138.28% | |||
| Normalized Diluted EPS | -126.13% | 143.68% | |||
| Average Basic Shares Outstanding | 2.07% | 0.95% | |||
| Average Diluted Shares Outstanding | -2.52% | 5.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
